AgriDyne Technologies Inc. sales and marketing update

Pharmakon Research International Inc., a subsidiary of DNX Corp. (DNXX), announced the availability of its first transgenic animal model, Biodigm-IGT, a genetically engineered mouse that expresses elevated insulin levels. Biodigm-IGT, which will be part of Pharmakon's preclinical testing service, screens experimental compounds for treating impaired glucose tolerance, commonly associated with Type II, or non-insulin-dependent, diabetes. The mice are produced by microinjecting purified DNA fragments containing the gene of interest into the pronucleus of fertilized eggs. ...